Want to join the conversation?
$VRTX's non-GAAP Opex increased to $306MM in 1Q16 compared to $246MM in the prior year. The increase was primarily due to increased cost related to the progression of the company's cystic fibrosis (CF) pipeline and increased investments in global commercial support for the launch of Orkambi drug.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.